

# System Changes to Implement Epoetin Alfa Biosimilar, Retacrit for End Stage Renal Disease (ESRD) and Acute Kidney Injury (AKI) Claims

MLN Matters Number: MM10839 Related Change Request (CR) Number: 10839

Related CR Release Date: August 3, 2018 Effective Date: January 1, 2019

Related CR Transmittal Number: R245BP Implementation Date: January 7, 2019

and R4105CP

## PROVIDER TYPES AFFECTED

This MLN Matters Article is intended for physicians, providers, and suppliers billing Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

## WHAT YOU NEED TO KNOW

Change Request (CR) 10839 updates the list of supplies, drugs, and labs included in the End Stage Renal Disease (ESRD) consolidated billing list and therefore included in the base rate payment for Acute Kidney Injury (AKI). This includes erythropoietin stimulating agents billed with the ESRD-specific Healthcare Common Procedure Coding System (HCPCS) or the non-ESRD specific HCPCS.

CR10839 adds Q5106 (Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units) to the list established in CR9987. Claims that include Q5106 with dates of service between July 1, 2018, and December 31, 2018 will need to be reprocessed. Make sure your billing staffs are aware of these changes.

#### BACKGROUND

On June 29, 2015, the Trade Preferences Extension Act of 2015 was enacted in which Section 808 amended Section 1861(s)(2)(F) of the Social Security Act (42 U.S.C. 1395x(s)(2)(F)) by extending renal dialysis services paid under Section 1881(b)(14) to beneficiaries with Acute Kidney Injury (AKI), effective January 1, 2017.

CRs9598 and 9814 implemented the initial requirements for this legislation.

MACs will not separately pay HCPCS code Q5106 (not found on the consolidated billing list) for AKI claims for Dates of Service (DOS) on or after July 1, 2018.





AKI claims are on Type of Bill 72X, submitted with condition code 84, CPT code G0491 and one of the following ICD-10 diagnosis codes:

- 1. N17.0 Acute kidney failure with tubular necrosis
- 2. N17.1 Acute kidney failure with acute cortical necrosis
- 3. N17.2 Acute kidney failure with medullary necrosis
- 4. N17.8 Other acute kidney failure
- 5. N17.9 Acute kidney failure, unspecified
- 6. T79.5XXA Traumatic anuria, initial encounter
- 7. T79.5XXD Traumatic anuria, subsequent encounter
- 8. T79.5XXS Traumatic anuria, sequela
- 9. N99.0 Post-procedural (acute)(chronic) renal failure

**Note**: Line should be indicated as covered and lines billed with modifier AY will not receive separate payment.

MACs will mass adjust AKI claims where HCPCS code Q5106 is present for DOS on or after July 1, 2018, through December 31, 2018. Mass adjustment should be completed within 90 days of the implementation date of CR10839.

#### ADDITIONAL INFORMATION

The official instruction, CR10839, issued to your MAC regarding this change consists of two transmittals. The first updates the Medicare Benefit Policy Manual and it is available at <a href="https://www.cms.gov/Regulations-and-">https://www.cms.gov/Regulations-and-</a>

<u>Guidance/Guidance/Transmittals/2018Downloads/R245BP.pdf</u>. The second updates the Medicare Claims Processing Manual and it is available at <a href="https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R4105CP.pdf">https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R4105CP.pdf</a>.

If you have questions, your MACs may have more information. Find their website at http://go.cms.gov/MAC-website-list.





## **DOCUMENT HISTORY**

Date of Change	Description
March 15, 2021	We replaced article links with related CR links.
August 3, 2018	Initial article released.

**Disclaimer:** This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2017 American Medical Association. All rights reserved.

Copyright © 2018, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.



